This new way of giving Tecentriq shows Roche’s focus on improving cancer treatment in India. The faster under-the-skin option for non-small cell lung cancer (NSCLC) aims to make patient visits easier and could help Roche gain an edge over competitors still using only IV methods.<\/p>\n
The subcutaneous Tecentriq injection takes about seven minutes to administer, a stark contrast to IV infusions that can last for hours. This is crucial in India, where cancer cases are rising. Studies show four out of five patients preferred the under-the-skin method over IV infusions, citing shorter clinic visits and less discomfort. This speed means healthcare providers could potentially treat five times more patients in the same amount of time. This aligns with a global trend toward quicker, more convenient oncology treatments.<\/p>\n
Roche’s move places Tecentriq in India’s growing immunotherapy market, with lung cancer being a key area. Tecentriq competes with drugs like Merck’s Keytruda, Bristol Myers Squibb’s Opdivo, and AstraZeneca’s Imfinzi. While these rivals are established, many still use IV delivery, though subcutaneous versions are appearing. For example, Merck has Keytruda Qlex (SC) and BMS has Opdivo Qvantig (SC) approved in Europe. AstraZeneca’s Imfinzi is mainly IV. Roche’s global parent company, F. Hoffmann-La Roche AG, is a major player with a significant market valuation. Government initiatives in India are also supporting increased access to cancer drugs.<\/p>\n
Tecentriq entered the market after competitors like Keytruda and Opdivo. Roche has also faced regulatory hurdles in India, including requests to revise the Phase IV trial protocol for Tecentriq SC. The company has had past issues regarding market exclusivity for its drugs in India. While the subcutaneous method offers speed, it can also lead to injection site reactions. The cost-effectiveness compared to IV therapy can also differ depending on the region and specific drug.<\/p>\n
Analysts watch Roche’s pipeline and diagnostics, but competition from biotech firms and generics remains a concern. Roche’s guidance remains for mid-single-digit sales growth and high-single-digit EPS growth in the medium term. For subcutaneous Tecentriq to succeed in India, it needs to prove it not only offers convenience but also improves adherence and patient outcomes, strengthening Roche’s position in the evolving cancer treatment field.<\/p>\n
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication\u2019s editorial stance.<\/p>\n","protected":false},"excerpt":{"rendered":"This new way of giving Tecentriq shows Roche’s focus on improving cancer treatment in India. The faster under-the-skin…\n","protected":false},"author":2,"featured_media":65203,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[35566,6717,35567,6724,477,35555,265,134,20824,6289,7780],"class_list":{"0":"post-65202","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-7-minute-treatment","9":"tag-atezolizumab","10":"tag-cancer-care-india","11":"tag-immunotherapy","12":"tag-lung-cancer","13":"tag-nsclc","14":"tag-oncology","15":"tag-roche","16":"tag-roche-pharma-india","17":"tag-subcutaneous-injection","18":"tag-tecentriq"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116572383205119811","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/65202","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=65202"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/65202\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/65203"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=65202"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=65202"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=65202"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}